Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00912288 · ClinicalTrials.gov registry record · Phase 3
A Phase 3 Efficacy Study Of Dimebon In Patients With Moderate To Severe Alzheimer's Disease
A Phase 3 study, sponsored by Pfizer.
- Terminated
- Registry status
- Phase 3
- Development phase
- 86
- Enrollment target
NCT00912288 is a Phase 3 study that was terminated before completion, run by Pfizer. The registered enrollment target is 86 participants.
The verdict
NCT00912288, a Phase 3 study, was terminated before completion, sponsored by Pfizer.
- TERMINATED
- Registry status
- Phase 3
- Development phase
- 86 participants
- Enrollment target
Study Summary
No Dimebon clinical data exist yet in patients with disease that has advanced to the moderate-to-severe stage. Therefore, this study evaluates the safety and efficacy of Dimebon in patients with moderate-to-severe AD who are receiving existing background therapy with memantine.
Interventions
- DRUG Dimebon 20 mg po TID
- DRUG Placebo po TID
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 86 participants |
| Start Date | 2009-09 |
| Est. Completion | 2010-08 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00912288
The ClinicalTrials.gov registry entry for NCT00912288 describes a study currently listed as terminated, categorized as Phase 3. The registered enrollment target is 86 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Pfizer, which has 1,845 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Dimebon 20 mg po TID is the first listed.
NCT00912288 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00912288 about?
NCT00912288 is a clinical study titled "A Phase 3 Efficacy Study Of Dimebon In Patients With Moderate To Severe Alzheimer's Disease". No Dimebon clinical data exist yet in patients with disease that has advanced to the moderate-to-severe stage. Therefore, this study evaluates the safety and efficacy of Dimebon in patients with moderate-to-severe AD who are receiving existing background therapy with memantine.
What is the current status of trial NCT00912288?
This trial is currently terminated. It is a Phase 3 study. The enrollment target is 86 participants. The study started on 2009-09. Estimated completion is 2010-08.
What interventions are being tested in trial NCT00912288?
The interventions under investigation include: Dimebon 20 mg po TID (DRUG), Placebo po TID (DRUG).
Who is sponsoring clinical trial NCT00912288?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.